Stuart Gallagher

Employment

• NSW Health Medical Officer
  2022 - Present
• Centenary Institute
  2015 - 2021
• Kolling Institute of Medical Research Researcher
  2012 - 2015
• Institut Curie Post Doctoral Fellow
  2009 - 2011

Education

• The University of Sydney MD
  2018 - 2021
• University of Sydney PhD
  2004 - 2008
• University of Western Australia Graduate Diploma in Microbiology
  2003 - 2003
• University of Western Australia BSc Agriculture (Hons)
  1994 - 1997

Projects & Funding

Projects & funding information is unavailable.

Publications (48)

• BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment
  Pigment Cell & Melanoma Research 2024 DOI: 10.1111/pcmr.13174
  +Save
• Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma
  Journal of Investigative Dermatology 2022 DOI: 10.1016/j.jid.2021.09.030
  +Save
• Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis
  Pathology 2021 DOI: 10.1016/j.pathol.2021.02.012
  +Save
• A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
  Journal of Investigative Dermatology 2021 DOI: 10.1016/j.jid.2020.12.038
  +Save
• Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma
  2021 DOI: 10.1101/2021.08.23.457344
  +Save
• Sex bias of females in survival from cancer and infections. Is X the answer?
  British Journal of Cancer 2021 DOI: 10.1038/s41416-020-01245-1
  +Save
• EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
  Jessamy C. Tiffen, Stuart J. Gallagher, Fabian V. Filipp +10 more
  Journal of Investigative Dermatology 2020 DOI: 10.1016/j.jid.2020.02.042
  +Save
• Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts
  Cancers 2020 DOI: 10.3390/cancers12082082
  +Save
• Melanoma Vaccines
  Cutaneous Melanoma 2020 DOI: 10.1007/978-3-030-05070-2_37
  +Save
• Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma
  International Journal of Cancer 2020 DOI: 10.1002/ijc.33000
  +Save
• Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?
  Pigment Cell and Melanoma Research 2020 DOI: 10.1111/pcmr.12870
  +Save
• Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition
  International Journal of Oncology 2020 DOI: 10.3892/ijo.2020.5031
  +Save
• Melanoma Vaccines
  Cutaneous Melanoma, Sixth Edition 2020 DOI: 10.1007/978-3-030-05070-2_37
  +Save
• Shedding light on dabrafenib-induced fevers in patients with melanoma.
  The Lancet. Oncology 2019 DOI: 10.1016/s1470-2045(19)30681-3
  +Save
• C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo
  Pigment Cell and Melanoma Research 2019 DOI: 10.1111/pcmr.12807
  +Save
• Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
  Abdullah Al Emran, Aniruddha Chatterjee, Euan James Rodger +4 more
  Trends in Immunology 2019 DOI: 10.1016/j.it.2019.02.004
  +Save
• SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.
  Nature communications 2018 DOI: 10.1038/s41467-018-05966-z
  +Save
• Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma.
  Aniruddha Chatterjee, Euan James Rodger, Antonio Ahn +8 more
  iScience 2018 DOI: 10.1016/j.isci.2018.05.021
  +Save
• HDAC inhibitors restore BRAF‐inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
  International Journal of Cancer 2018 DOI: 10.1002/ijc.31199
  +Save
• Simulation of melanoblast displacements reveals new features of developmental migration
  Development 2018 DOI: 10.1242/dev.160200
  +Save